Microvision, Inc. Prices $7.9 Million Public Offering of Common Stock

Microvision, Inc. Prices $7.9 Million Public Offering of Common Stock

REDMOND, Wash.--(BUSINESS WIRE)--Nov. 13, 2006--Microvision, Inc. (NASDAQ:MVIS) announced today the pricing of its public offering of 3,317,567 shares of its common stock at a price of $2.39 per share of common stock before underwriting discounts and commissions. Gross proceeds before underwriter fees and offering expenses are expected to be approximately $7.9 million.

MDB Capital Group LLC is acting as the sole underwriter of the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A prospectus supplement relating to these securities has been filed with the Securities and Exchange Commission. The offering of the shares of common stock may be made only by means of the prospectus supplement and related prospectus, copies of which will be available from MDB Capital Group LLC, 401 Wilshire Boulevard, Suite 1020, Santa Monica, California 90401 or by calling MDB Capital Group at 310-526-5000.

About Microvision: www.microvision.com

Headquartered in Redmond, Wash., Microvision Inc. is the global leader in the development of high-resolution displays and imaging systems based on the company's proprietary silicon micro-mirror technology. The company's technology has applications in a broad range of military, medical, industrial, professional and consumer products.

Forward-Looking Statements Disclaimer

Certain statements contained in this release, including those relating to the closing of proposed financing, as well as statements containing words like "expects," are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: capital market risks, our ability to raise additional capital when needed; market acceptance of our technologies and products; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; our dependence on the defense industry and a limited number of government development contracts; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our products; potential product liability claims, risks related to Lumera's business and the market for its equity and other risk factors identified from time to time in the company's SEC reports and other filings, including the Company's Annual Report on Form 10-K filed with the SEC. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.


  1. Dilution sucks but its necessary to pay off the notes which are coming due in March '07. Why the big discount on the share price?


Post a Comment